homochlorcyclizine

Homochlorcyclizine is a first-generation antihistamine of the diphenylmethylpiperazine group, marketed in Japan since 1965 for the treatment of allergic conditions such as urticaria, allergic rhinitis, and pruritus associated with skin diseases (eczema, dermatitis). It acts primarily as a competitive antagonist at histamine H1 receptor, thereby inhibiting the effects of histamine in allergic responses. In addition to its antihistaminic activity, it exhibits antimuscarinic (anticholinergic), antidopaminergic, and antiserotonergic properties. Homochlorcyclizine also inhibits bradykinin-induced contractions and partially blocks slow-reacting substance of anaphylaxis (SRS-A)–induced contractions. The drug is administered orally and is known for sedative side effects typical of first-generation antihistamines[1][3][4][5][6][7][8].

Other names

homochlorcyclizinumhomoclorociclizina